PT INTL DEV (00372) released its annual performance, with a net loss attributable to shareholders of HK$250 million, an increase of 42.25% year-on-year.

18:28 01/07/2026

BaoDe International Development (00372) announced its annual results for the fiscal year ending on March 31, 2026. The group achieved a revenue of HK$103 million, a decrease of 27.05% year-on-year. The company's net loss attributable to owners amounted to HK$250 million, an increase of 42.25% year-on-year. Loss per share was 82.68 HK cents.

PT INTL DEV (00372) announced its annual results for the year ending March 31, 2026. The group recorded a revenue of HK $103 million, a decrease of 27.05% compared to the previous year. The company's attributable loss was HK $250 million, an increase of 42.25% compared to the previous year, with a loss per share of 82.68 HK cents. The announcement stated that the loss for the year was mainly due to fair value losses on unrealized financial instruments, particularly investments in the AFC Mercury Fund and impairment losses on properties, plant, and equipment related to the petrochemicals division, as well as impairment losses on right-of-use assets.

Shanghai Pharmaceuticals Holding (02607): Shanghai Pharmaceuticals Group increased its holdings in the company's H shares by a total of 74 million shares through Shanghai Pharmaceuticals International.

Hunan Jiudian Pharmaceutical (300705.SZ): Two products obtained drug registration certificates.

TRISTATE HOLD(00458) and ABG, along with related franchisees, have recently had disputes regarding distribution and/or clearance rights of Nautica, Spyder, and Reebok brand products.

Hunan Jiudian Pharmaceutical (300705.SZ): Two products obtained drug registration certificates.

TRISTATE HOLD(00458) and ABG, along with related franchisees, have recently had disputes regarding distribution and/or clearance rights of Nautica, Spyder, and Reebok brand products.